GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » NonCurrent Deferred Liabilities

Roquefort Therapeutics (LSE:ROQ) NonCurrent Deferred Liabilities : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Roquefort Therapeutics's non-current deferred liabilities for the quarter that ended in Dec. 2023 was £0.00 Mil.

Roquefort Therapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Roquefort Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics NonCurrent Deferred Liabilities Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities - - - - -

Roquefort Therapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics (LSE:ROQ) Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines